Menu Back toLS34: Impact of COVID-19 on US Clinical Studies Conducted by Japan-Based Pharmaceutical Companies
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
18th DIA Japan Annual Meeting 2021
All prices are exclusive of 10% Japanese consumption tax
LS34: Impact of COVID-19 on US Clinical Studies Conducted by Japan-Based Pharmaceutical Companies
- SOCIUM Inc., Japan
- Project Manager
- Project Planning & Management Forum NY Chapter, United States
- Senior Specialist Clinical Research
- MSD K.K., Japan
- Director, Clinical Operations
- ONO PHARMACEUTICAL CO., LTD., United States